药物之间的相互作用1329045个记录(本栏目收费,不能展示细节,电话13136136841)
药物之间的相互作用
Dioxaphetyl butyrate
Benzydamine
Ertugliflozin may increase the excretion rate of Benzydamine which could result in a lower serum level and potentially a reduction in efficacy.
Dioxaphetyl butyrate
Vilanterol
Ertugliflozin may increase the excretion rate of Vilanterol which could result in a lower serum level and potentially a reduction in efficacy.
Dioxaphetyl butyrate
Idebenone
Ertugliflozin may increase the excretion rate of Idebenone which could result in a lower serum level and potentially a reduction in efficacy.
Dioxaphetyl butyrate
Tasimelteon
Ertugliflozin may increase the excretion rate of Tasimelteon which could result in a lower serum level and potentially a reduction in efficacy.
Dioxaphetyl butyrate
Vortioxetine
Ertugliflozin may increase the excretion rate of Vortioxetine which could result in a lower serum level and potentially a reduction in efficacy.
Dioxaphetyl butyrate
Corifollitropin alfa
Ertugliflozin may increase the excretion rate of Corifollitropin alfa which could result in a lower serum level and potentially a reduction in efficacy.
Dioxaphetyl butyrate
Ceftolozane
Ertugliflozin may increase the excretion rate of Ceftolozane which could result in a lower serum level and potentially a reduction in efficacy.
Dioxaphetyl butyrate
Macitentan
Ertugliflozin may increase the excretion rate of Macitentan which could result in a lower serum level and potentially a reduction in efficacy.
Dioxaphetyl butyrate
Trametinib
Ertugliflozin may increase the excretion rate of Trametinib which could result in a lower serum level and potentially a reduction in efficacy.
Dioxaphetyl butyrate
Glycerol phenylbutyrate
Ertugliflozin may increase the excretion rate of Glycerol phenylbutyrate which could result in a lower serum level and potentially a reduction in efficacy.
Dioxaphetyl butyrate
Formestane
Ertugliflozin may increase the excretion rate of Formestane which could result in a lower serum level and potentially a reduction in efficacy.
Dioxaphetyl butyrate
Certolizumab pegol
Ertugliflozin may increase the excretion rate of Certolizumab pegol which could result in a lower serum level and potentially a reduction in efficacy.
Dioxaphetyl butyrate
Teduglutide
Ertugliflozin may increase the excretion rate of Teduglutide which could result in a lower serum level and potentially a reduction in efficacy.
Dioxaphetyl butyrate
Aclidinium
Ertugliflozin may increase the excretion rate of Aclidinium which could result in a lower serum level and potentially a reduction in efficacy.
Dioxaphetyl butyrate
Peginesatide
Ertugliflozin may increase the excretion rate of Peginesatide which could result in a lower serum level and potentially a reduction in efficacy.
Dioxaphetyl butyrate
Ruxolitinib
Ertugliflozin may increase the excretion rate of Ruxolitinib which could result in a lower serum level and potentially a reduction in efficacy.
Dioxaphetyl butyrate
Deferiprone
Ertugliflozin may increase the excretion rate of Deferiprone which could result in a lower serum level and potentially a reduction in efficacy.
Dioxaphetyl butyrate
Tiopronin
Ertugliflozin may increase the excretion rate of Tiopronin which could result in a lower serum level and potentially a reduction in efficacy.
Dioxaphetyl butyrate
Plerixafor
Ertugliflozin may increase the excretion rate of Plerixafor which could result in a lower serum level and potentially a reduction in efficacy.
Dioxaphetyl butyrate
Methylnaltrexone
Ertugliflozin may increase the excretion rate of Methylnaltrexone which could result in a lower serum level and potentially a reduction in efficacy.